Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
$0.07
$0.06
$1.17
$37K1.1315.69 million shs96,558 shs
Neuralstem, Inc. stock logo
CUR
Neuralstem
$0.78
+2.6%
$1.06
$1.10
$13.78
$1.64M1.81236,278 shs77,798 shs
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
$0.17
$0.17
$0.11
$0.35
$12.89M1.133.16 million shs2.95 million shs
Vical Incorporated stock logo
VICL
Vical
$1.24
$0.60
$1.47
$21.01M0.321.44 million shs35,024 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Neuralstem, Inc. stock logo
CUR
Neuralstem
+5.41%+4.18%+7.27%+11.76%-83.00%
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
0.00%0.00%0.00%0.00%0.00%
Vical Incorporated stock logo
VICL
Vical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/AN/AN/AN/A
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/AN/AN/AN/AN/AN/AN/AN/A
Vical Incorporated stock logo
VICL
Vical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
0.00
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
0.00
N/AN/AN/A
Vical Incorporated stock logo
VICL
Vical
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/AN/AN/AN/A$0.23 per shareN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K6.30N/AN/A$6.64 per share0.12
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/AN/AN/AN/A$0.12 per shareN/A
Vical Incorporated stock logo
VICL
Vical
$1.62M0.00N/AN/A$1.82 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/A0.00N/A-39,417.64%-170.51%-110.16%N/A
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
-$30.77M-$0.50N/AN/AN/A-898.31%-286.73%N/A
Vical Incorporated stock logo
VICL
Vical
-$16.25M-$0.81N/AN/AN/A-1,002.10%-29.46%-27.85%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/AN/AN/AN/AN/A
Vical Incorporated stock logo
VICL
Vical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
N/A
1.58
1.58
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
N/A
0.65
0.65
Vical Incorporated stock logo
VICL
Vical
N/A
36.84
36.84

Institutional Ownership

CompanyInstitutional Ownership
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
7.33%
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
7.03%
Vical Incorporated stock logo
VICL
Vical
29.06%

Insider Ownership

CompanyInsider Ownership
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
3.70%
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
43.80%
Vical Incorporated stock logo
VICL
Vical
4.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allena Pharmaceuticals, Inc. stock logo
ALNA
Allena Pharmaceuticals
35122.08 million117.57 millionNot Optionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
Aevi Genomic Medicine, LLC stock logo
GNMX
Aevi Genomic Medicine
1477.71 millionN/AOptionable
Vical Incorporated stock logo
VICL
Vical
3022.84 millionN/ANot Optionable

Recent News About These Companies

Allena Pharmaceuticals stock logo

Allena Pharmaceuticals NASDAQ:ALNA

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Aevi Genomic Medicine stock logo

Aevi Genomic Medicine NASDAQ:GNMX

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Vical stock logo

Vical NASDAQ:VICL

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.